Table 4

Treatment retention in (A) switchers vs non-switchers and (B) switchers vs historic cohort. Results from univariable and multivariable Cox regression analysis (HR, with 95% CI) stratified by indication

RAPsAAxSpA
HRP valuesHRP valuesHRP values
A. Switchers vs non-switchers*
 Crude0.68 (0.51 to 0.91)0.00050.42 (0.24 to 0.73)0.00190.89 (0.49 to 1.60)0.70
 Adjusted†0.81 (0.59 to 1.11)0.180.55 (0.28 to 1.07)0.0790.92 (0.50 to 1.73)0.82
B. Switchers vs historic comparison cohort*
 Crude1.73 (1.36 to 2.19)<0.00011.93 (1.26 to 2.96)0.00242.29 (1.45 to 3.61)0.0003
 Adjusted†1.76 (1.39 to 2.23)<0.00012.15 (1.42 to 3.25)0.00032.37 (1.51 to 3.73)0.0002
  • *Number of patients included in cohorts: RA (switchers 684 patients/non-switchers 264/historic cohort 1239), PsA (253/49/364), AxSpA (217/81/412), patients with missing data regarding remission status excluded.

  • †Adjusted for gender, age, methotrexate use (yes/no), remission (yes/no), comorbidities (≥1/0), ETA start year (1998-2010/2011-2016). Remission defined as DAS28 <2.6 (RA, PsA), ASDAS <1.3 (AxSpA).

  • ASDAS, the Ankylosing Spondylitis Disease Activity Score; AxSpA, axial spondyloarthritis; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score (four variables, CRP-based); ETA, originator etanercept; PGS, Patient’s globalscore; PsA, psoriatic arthritis; RA, rheumatoid arthritis.